SSP-002358

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

Proton pump inhibitor, Serotonin 4 receptor agonist

‹

›

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.

HRD	Solid Tumor	HRD	Solid Tumor	SSP-002358 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) SSP-002358 Sensitive : D AACR 2023 - 1wk	SSP-002358 Sensitive: D – Preclinical AACR 2023 - 1 week SSP-002358 Sensitive : D AACR 2023 - 1 week - (New D)
HRD	Solid Tumor	HRD	Solid Tumor	olaparib + SSP-002358 Sensitive: D – Preclinical AACR 2023 - 1 week (New D) olaparib + SSP-002358 Sensitive : D AACR 2023 - 1wk	olaparib + SSP-002358 Sensitive: D – Preclinical AACR 2023 - 1 week olaparib + SSP-002358 Sensitive : D AACR 2023 - 1 week - (New D)

Associations
(2)